MedTrace Logo

Exclusion of the Left Atrial Appendage (LAA) With the LAAx, Inc. TigerPaw System

NCT00962702 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2009-08-20

No results posted yet for this study

Summary

The dual primary safety and effectiveness outcomes for the use of The TigerPaw System include the rate of device related adverse and serious adverse events and the extent of complete exclusion of the LAA with minimal residual cavity.

Conditions

Interventions

DEVICE

LAAx TigerPaw System

Exclusion of Left Atrial Appendage

Sponsors & Collaborators

  • LAAx, Inc.

    lead INDUSTRY

Principal Investigators

  • Mark Slaughter, MD · University of Louisville

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-08-31
Primary Completion
2009-12-31
Completion
2010-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00962702 on ClinicalTrials.gov